Resamirigene bilparvovec
| Gene therapy | |
|---|---|
| Target gene | MTM1 |
| Vector | Adeno-associated virus serotype 8 |
| Clinical data | |
| Other names | AT132 |
| Routes ofadministration | Intravascular |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| UNII | |
Resamirigene bilparvovec (codename: AT132) is an experimentalgene therapy medication studied as a treatment for X-linked myotubular myopathy (XLMTM), a severe and usually fatal genetic disorder affecting mainly male infants and caused by a mutation in the MTM1 gene. The drug consists of a MTM1transgene encapsulated in a viral vector from the adeno-associated virus class (AAV8) and is administered to affected children as an intravenous infusion.
The treatment is being developed by Astellas Gene Therapies and is currently in a phase I/II clinical trial in the United States. As of October 2021, four children had died in the trial after experiencing liver failure linked to the treatment, and the trial has been placed on clinical hold by the U.S. Food and Drug Administration.[1][2]
References
- ^Philippidis A (2021-09-15). "Fourth Boy Dies in Trial of Astellas Gene Therapy Candidate". GEN - Genetic Engineering and Biotechnology News. Retrieved 2021-10-15.
- ^"Astellas Reports Update to September 1 Announcement on the ASPIRO Clinical Trial of AT132 in Patients with X-linked Myotubular Myopathy | Astellas Pharma Inc. GLOBAL WEBSITE". Astellas Pharma. 14 September 2021. Retrieved 2021-10-15.
 | This drug article relating to the musculoskeletal system is a stub. You can help Wikipedia by adding missing information. |
